Teriflunomide is a new peroral disease-modifying drug for multiple sclerosis (a review)

Boĭko O.V.; Stoliarov I.D.; Petrov A.M.; Boĭko A.N.

doi:https://doi.org/

Boĭko O.V.

Moskovskiĭ gorodskoĭ tsentr rasseiannogo skleroza na baze Gorodskoĭ klinicheskoĭ bol'nitsy #11

Stoliarov I.D.

Petrov A.M.

Kafedra éndoskopicheskoĭ khirurgii fakul'teta poslediplomnogo obrazovaniia MGMSU

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

Teriflunomide is a new peroral disease-modifying drug for multiple sclerosis (a review)

Authors:

Boĭko O.V., Stoliarov I.D., Petrov A.M., Boĭko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10‑2): 78‑81

Read: 6273 times

Contact the author

Table of contents

To cite this article:

Boĭko OV, Stoliarov ID, Petrov AM, Boĭko AN. Teriflunomide is a new peroral disease-modifying drug for multiple sclerosis (a review). S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10‑2):78‑81.

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Molecular mechanisms of acute disseminated encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11

The role of monocytes in the immunopathogenesis of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27

Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33

Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple sclerosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38

Features of the clinical course of multiple sclerosis as a factor in persistent disability. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44

Quantitative analysis of cerebrospinal fluid flow in multiple sclerosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50

Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):51-59

A clinical case of X-linked adrenoleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107

Artificial intelligence capabilities in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

Abstract:

Teriflunomide is a once-daily, orally administered, disease-modifying drug. The review presents the data concerning the mechanism of action, pharmacokinetics as well as results of clinical studies. Teriflunomide has received the regulatory approval in the USA, Argentina, Australia, South Korea, Chile and EU. The submission of a regulatory dossier is performed in Russia.

Keywords:

multiple sclerosis

teriflunomide

оral disease-modifying drug